The Priority Review

Clinical trials Brief

AstraZeneca registers Phase III trial of FDC laroprovstat/rosuvastatin in hypercholesterolemia

The study plans to enroll 204 participants and is expected to start on December 21, 2026. It aims to evaluate the effect on LDL-C and the safety and tolerability of the fixed-dose combination in lipid-lowering treatment-naïve patients.

Primary source

ClinicalTrials.gov registry record, November 12, 2026

A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients

Read the source: A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients clinicaltrials.gov

Machine-summarized from the source above; not independently reported. How we use automation